| Literature DB >> 30607559 |
Detlef Brehmer1,2,3, Robert Bodlaj4, Friedemann Gerhards5.
Abstract
BACKGROUND: Weak or inward-bent cartilage of the nasal sidewall at the level of the internal nasal valve (INV) can produce narrowness or collapse of the nasal valve. This is a common cause of impaired nasal breathing during daily activities and there is also an established connection between nasal obstruction and snoring. The condition is often difficult to treat, although even a small enlargement of the lumen at the nasal valve can lead to a significant improvement in the ease of nasal breathing.Entities:
Keywords: Nasal valve; Nose score; Radiofrequency therapy; Snoring
Mesh:
Year: 2019 PMID: 30607559 PMCID: PMC6426809 DOI: 10.1007/s00405-018-05270-y
Source DB: PubMed Journal: Eur Arch Otorhinolaryngol ISSN: 0937-4477 Impact factor: 2.503
Fig. 1Schematic diagram summarizing the study design. WatchPAT200: wrist-worn device measuring peripheral arterial tone. NOSE nasal obstruction symptom evaluation scale, LOCF last observation carried forward
Fig. 2The RF remodeling platform
Fig. 3Handpiece treatment device
Fig. 4Treatment points
Medium score (and interquartile range) for the Nasal Obstruction Symptom Evaluation Scale (NOSE) and the Snore Outcomes Survey (SOS; selected items) at study enrollment (t1) and 30 days after radiofrequency treatment (t2); sample size and significance level of the Wilcoxon signed-rank test
|
|
|
|
| |
|---|---|---|---|---|
| Mdn (IQR) | Mdn (IQR) | |||
| Nasal Obstruction Symtom Evaluation Scale (NOSE) | 65.00 (21.25) | 30.00 (35.00) | 30 |
|
| Snore Outcomes Survey (SOS; selected items) | 66.67 (32.29) | 47.92 (40.63) | 25 |
|
Bold—Significance level p: probability that the difference between the data collected at the measurement time points mentioned occured randomly or by chance, but is instead attributed to the low energy radiofrequency remodeling treatment (probabilty of error α)
Statistical comparisons by Wilcoxon signed-rank test; p significance level (one-tailed) concerning the difference of scores at time points t1 and t2
Mdn median, IQR interquartile range, N number of participants
Medium score (and interquartile range) for the Nasal Obstruction Symptom Evaluation Scale (NOSE), the Snore Outcomes Survey (SOS; selected items), the 20-Item Sino-Nasal Outcome Test, German Adapted Version (SNOT-20 GAV), the EQ-5D-5L questionnaire and parameters of disordered breathing and snoring during sleep assessed by the WatchPAT200 at study enrollment (t1) and 90 days after radiofrequency treatment (t3); sample size and significance level of the Wilcoxon signed-rank test
|
|
|
|
| |
|---|---|---|---|---|
| Mdn (IQR) | Mdn (IQR) | |||
| Nasal Obstruction Symtom Evaluation Scale (NOSE) | 65.00 (20.00) | 30.00 (25.00) | 31 |
|
| Snore Outcomes Survey (SOS; selected items) | 66.67 (31.25) | 41.67 (29.17) | 27 |
|
| 20-Item Sino-Nasal Outcome Test, German Adapted Version (SNOT-20 GAV) | ||||
| Total Score (TS) | 30.00 (26.00) | 19.00 (16.00) | 31 |
|
| Primary Nasal Symptoms (PNS) | 32.00 (28.00) | 20.00 (16.00) | 31 |
|
| Secondary Rhinogenic Symptoms (SRS) | 20.00 (20.00) | 10.00 (10.00) | 31 |
|
| Generic Quality of Life (GQL) | 28.89 (28.89) | 20.00 (24.44) | 31 |
|
| EuroQoL group questionnaire for generic quality of life (EQ-5D-5L) | ||||
| Visual Analog Scale (VAS) | 80.00 (22.50) | 80.00 (21.00) | 29 |
|
| Sum Score (SS) | 95.00 (20.00) | 95.00 (10.00) | 31 |
|
| WatchPAT200 | ||||
| Apnea–Hypopnea Index (AHI) | 8.21 (10.39) | 8.15 (16.96) | 31 | 0.197 |
| Mean snoring intensity (dB) | 41.00 (1.00) | 41.00 (1.00) | 30 | 0.497 |
| Percent of sleeping time spent with a snoring intensity > 45 dB | 2.25 (5.18) | 2.45 (5.13) | 30 | 0.237 |
Bold—Significance level p: probability that the difference between the data collected at the measurement time points mentioned occured randomly or by chance, but is instead attributed to the low energy radiofrequency remodeling treatment (probabilty of error α)
Statistical comparisons by Wilcoxon signed-rank test; p significance level (one-tailed) concerning the difference of scores at time points t1 and t3
Mdn median, IQR interquartile range, N number of participants
Fig. 5Development of nasal obstruction and snoring: mean (± SEM) of the NOSE and SOS score at pre- and post-treatment assessment time points. NOSE Nasal Obstruction Symptom Evaluation Scale, SOS Snore Outcomes Survey (selected items), RF radiofrequency